MDCX (Medicus Pharma) Research & Development: $17.14 Mil (TTM As of Mar. 2026)


MDCX Medicus Pharma Ltd MDCX
13 GF Score
Price $0.42
! 2 Warning Signs
View Full Analysis

What is Medicus Pharma Research & Development?

Medicus Pharma MDCX +4.07% 13 Research & Development is $17.14 Mil as of Mar. 2026. GuruFocus rates MDCX with a GF Score™ of 13/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medicus Pharma's Research & Development for the three months ended in Mar. 2026 was $2.70 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $17.14 Mil.

Medicus Pharma  (NAS:MDCX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medicus Pharma Research & Development Related Terms

Medicus Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Medicus Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicus Pharma Research & Development Chart

Medicus Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
1.18 0.65 0.19 3.53 16.44

Medicus Pharma Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.01 1.44 10.40 2.59 2.70
MDCX
13GF Score
Medicus Pharma Ltd MDCX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicus Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $17.14 Mil mean?
Medicus Pharma (MDCX) has a Research & Development of $17.14 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Medicus Pharma and its competitors.
Is Medicus Pharma's Research & Development too high?
Medicus Pharma's current Research & Development is $17.14 Mil. Overall, Medicus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Medicus Pharma's Research & Development compare to NSRX and MIRA?
Medicus Pharma's Research & Development of $17.14 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medicus Pharma and its competitors. Medicus Pharma's current Research & Development is $17.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicus Pharma stock overvalued right now?
Medicus Pharma (MDCX) has a current Research & Development of $17.14 Mil. The current Research & Development is $17.14 Mil. Medicus Pharma's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medicus Pharma (MDCX), the current Research & Development is $17.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicus Pharma Business Description

Address 100 King Street West, Suite 3400, One First Canadian Place, Toronto, ON, CAN, M5X 1A4
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
13GF Score

Get the complete analysis for MDCX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price